Compare Dell Technologies Inc (DELL) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Johnson & Johnson — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Johnson & Johnson for 129 Days on average.
| DELL | JNJ | |
|---|---|---|
Market Cap | $365.31B | $618.09B |
Volume | 5,121,365 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $588.67 | $278.43 |
52-Week Low | $111.10 | $186.00 |
Typical Hold Time | 57 Days | 129 Days |
Enterprise Value | $388.20B | $646.37B |
Dividend Yield | 0.44% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $574.74, down 0.73% on the day, with a bullish technical signal and strong fundamental momentum. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $7.04 surpassing expectations by 43%. The company's AI server business is a key growth driver, with a backlog surging to $95 billion and fiscal 2027 revenue guidance raised to approximately $192 billion. Positive analyst sentiment is reflected in a 55.56% buy rating, though the stock trades above the consensus price target of $566.35.
The outlook for Dell is optimistic, driven by explosive AI server demand and robust financial performance. Investment opportunities include continued revenue growth and margin expansion, supported by a capital-light model. Risks include execution challenges in meeting high demand, competitive pressures, and market volatility. The stock's current valuation at a P/E of 33.42 may limit near-term upside if growth moderates.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
